ClinicalTrials.gg
CompletedNCT05554913Updated Oct 18, 2024

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

A Phase 2/3 interventional study of QL0911 and Placebo in Chemotherapy-induced Thrombocytopenia, sponsored by Qilu Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies in Thrombocytopenia with a site in China — 42 open to participants now, 45 under way, 10 of them phase 3. Thrombocytopenia · China.

Enrollment
51st of 96
63 · median 82
Started
2022
with 12 others
Phase 2/3
12 of 108
4 open now
Registered
60th of 108
by date
Lead sponsor
3 of 108
Qilu Pharmaceutical Co., Ltd.

Among the 108 studies in Thrombocytopenia with a site in China, this one is the 51st largest by enrollment of the 96 interventional ones that give a count, is one of 13 that started in 2022, is one of 12 in phase 2/3, and was the 60th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

42 of the 108 studies in Thrombocytopenia with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Thrombocytopenia with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of QL0911 to prevention chemotherapy-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia occurs as a side effect of chemotherapy treatments.

Read the detailed description

For the phase III study, a double-blind randomized, placebo controlled, parallel-group design will be conducted to evaluate the efficacy and safety of QL0911 . Each subject will be randomly assigned to either Arm A (QL0911) or Arm B (placebo) in 2:1 ratio.The primary objective is to compare the effective rates of the two treatment arms. The study will consist of a screening period of up to 4 weeks, a treatment period of 2 planned cycles of chemotherapy, a follow-up visit of 2 weeks.

03

Conditions studied

  • Chemotherapy-induced Thrombocytopenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years old;
  • Histopathological or cytological examination confirmed solid tumor or lymphoma (including NSCLC, breast cancer, bladder cancer, pancreatic cancer, etc.), chemotherapy cycle of 21 days, and using of one or more of the following chemotherapy drugs: gemcitabine; Platinum, including carboplatin, nedaplatin, cisplatin, lobaplatin, etc.; Anthracyclines, including doxorubicin, daunorubicin, epirubicin, etc.; Taxa, including paclitaxel, docetaxel, etc.
  • The current chemotherapy regimen should be consistent with that of the previous chemotherapy cycle, including the chemotherapy drugs and the dosages, without adding or subtracting drugs or dosages;
  • At least two counts with an interval of more than 24 hours in the chemotherapy cycle before enrollment was grade 2 or higher thrombocytopenia;
  • The platelet count was between 75×10\^9/L-150×10\^9/L (including both ends) 1 day before chemotherapy or the day of Randomization;
  • At the time of screening, the expected survival time is ≥12 weeks, and the current chemotherapy regimen can be accepted for at least 2 cycles;
  • (ECOG) performance status of 0, 1, or 2;
  • Fully understand and comply with the requirements of this study, and voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  • Suffering from other hematopoietic system diseases besides lymphoma, including leukemia, primary immune thrombocytopenia, myeloproliferative diseases, multiple myeloma and myelodysplastic syndromes, etc.
  • Have experienced thrombocytopenia caused by non-tumor chemotherapeutics within 6 months before screening,Including, but not limited to, EDTA-dependent pseudothrombocytopenia, hypersplenism, infection, and bleeding, etc.
  • Brain tumors, ,bone marrow invasion or bone marrow ;
  • Receiving radiotherapy or have received abdominal pelvic or sternum radiotherapy within 3 months;
  • Any arterial or venous thrombosis occurred within 6 months before screening;
  • Severe cardiovascular disease (e.g., Heart Function Score Class III-IV), arrhythmias such as atrial fibrillation that increase the risk of thrombosis, coronary stenting, angioplasty, and coronary artery bypass grafting within the previous 6 months were screened;
  • Clinical manifestations of severe bleeding (such as gastrointestinal bleeding, etc.) within 4 weeks before the first administration of the experimental drug;
  • Received transfusion within 5 days before randomization/enrollment;
  • Received thrombopoietin receptor agonist treatment within 4 weeks, human recombinant thrombopoietin (rhTPO) or rhIL-11 within 4 weeks,other Chinese medicines with the effect of raising blood plate within 1 week before the administration of the experimental drug;
  • Used heparin, warfarin, aspirin and other anticoagulant drugs within 7 days before the first dose except for the purpose of sealing the tube;
  • Received bone marrow transplantation or stem cell infusion within 1 year before screening;
  • Patients with antibody positive and detection of HCV-RNA exceeding the upper limit, patients with surface antigen positive and detection of HBV-DNA exceeding the upper limit, patients with severe cirrhosis, antibody positive and syphilis antibody positive;
  • The absolute value of neutrophils in the screening period\<1.5×10\^9/L, \<90g/L;
  • Total greater than 3X ; [ALT] and aspartate aminotransferase [AST] greater than 3X ULN for subjects without liver metastases or greater than or equal to 5X ULN for subjects with liver metastases during screening;
  • Serum creatinine concentration ≥1.5ULN or ≤45ml/min ();
  • Severe drug allergic reactions;
  • Used any drug within 3 months before the administration of the experimental drug;
  • Planning pregnancy, pregnancy, or suckling period;
  • The investigator judged that the patients are not suitable for participating in this trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    QL0911

    The study in a 2:1 randomization ratio(40 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

    Drug: QL0911

  • Placebo comparator
    Placebo

    The study in a 2:1 randomization ratio(20 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

    Drug: Placebo

Interventions

  • DrugQL0911

    This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Proportion of patients who had an efficacy response during the double-blind period

    Time frame: 42 days

Secondary outcomes

  1. Lowest and highest platelet count

    Time frame: 42 days

  2. Bleeding score(Revised WHO grading system)

    Time frame: 42 days

  3. Proportion of patients with platelet count < 50×10^9/L per cycle

    Time frame: 42 days

07

Study locations

1 site
  • Shanghai East Hospital
    Shanghai, Shanghai 200120, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Feb 2024, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2022
First posted
Sep 26, 2022
StartActual
Nov 8, 2022
Primary completionActual
Feb 20, 2024
CompletionActual
Feb 20, 2024
Last update
Oct 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05554913
Responsible party
Sponsor
First posted
Sep 26, 2022
Start date
Nov 8, 2022
Primary completion
Feb 20, 2024
Completion
Feb 20, 2024
Last update
Oct 18, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QL0911

Start the discussion